<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355264</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-007</org_study_id>
    <nct_id>NCT00355264</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency</brief_title>
  <official_title>Phase 2, Multicenter, Open Label Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to Primary BH4 Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability of Phenoptin to control blood&#xD;
      phenylalanine levels in subjects who have hyperphenylalaninemia due to a primary BH4&#xD;
      deficiency and to evaluate the safety of Phenoptin in this population. Some subjects were&#xD;
      receiving non-registered formulations of BH4 at enrollment and this treatment was suspended&#xD;
      after Part 1 and within one day the subjects started Phenoptin at approximately the same&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within 4 weeks of completing screening assessments to determine eligibility, subjects will be&#xD;
      enrolled in the study. The study will be conducted in two parts.&#xD;
&#xD;
      Part 1: After screening, all subjects will be followed for two weeks without modification of&#xD;
      their baseline medical or dietary care.&#xD;
&#xD;
      Part 2: Beginning at Week 2, subjects who were receiving non-registered formulations of BH4&#xD;
      at enrollment will suspend this treatment and within one day will start Phenoptin at&#xD;
      approximately the same dose of the non-registered BH4 formulation. Subjects not receiving BH4&#xD;
      at enrollment will begin treatment with Phenoptin at approximately 5 mg/kg/day, given orally,&#xD;
      prior to meals.&#xD;
&#xD;
      At the discretion of the Investigator, the Phenoptin dose may be adjusted up or down at the&#xD;
      Week 6 visit to control blood Phe levels (&lt;360 µmol/L), or to optimize the clinical effect.&#xD;
      The maximum dose allowed will be approximately 20 mg/kg/day. All subjects will receive&#xD;
      Phenoptin for a total of 8 weeks. Subjects will be instructed to continue their usual diet&#xD;
      without modification. Study visits will occur every other week.&#xD;
&#xD;
      Tyrosine, biopterin and neopterin will be analyzed at the following visits: Week 0&#xD;
      (enrollment), Week 2 (prior to dosing with Phenoptin), Week 8 (after 6 weeks of treatment&#xD;
      with Phenoptin) and Week 10 (after 8 weeks of treatment with Phenoptin).During each visit,&#xD;
      blood Phe level will be measured (2.5-5 hours after a meal), and safety evaluations will be&#xD;
      performed. Safety will be assessed by monitoring adverse events and vital signs, performing&#xD;
      physical examinations, assessing signs and symptoms of primary BH4 deficiency (i.e.,&#xD;
      neurological symptoms such as seizures, changes in muscle tone, weakness, etc.) and clinical&#xD;
      laboratory tests (chemistry, hematology and urinalysis).&#xD;
&#xD;
      Extension: Upon completion of 8 weeks of treatment (i.e., at the Week 10 visit), subjects&#xD;
      will be offered the option to continue treatment with Phenoptin in an extension of this&#xD;
      study. Participation in the study extension will continue until one of the following occurs:&#xD;
&#xD;
        1. the subject withdraws consent and discontinues from the study,&#xD;
&#xD;
        2. the subject is discontinued from the study at the discretion of the investigator,&#xD;
&#xD;
        3. the study drug is available through the appropriate marketing approval, or&#xD;
&#xD;
        4. the study is terminated.&#xD;
&#xD;
      During the extension period, study drug will be dispensed to subjects monthly, and study&#xD;
      visits will be required every 3 months. The Phenoptin dose may be adjusted at any visit&#xD;
      during the study extension at the discretion of the Investigator. The maximum dose allowed&#xD;
      will be approximately 20 mg/kg/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Outcomes were to be evaluated for all subjects with primary BH4 disease. Outcomes were also evaluated based on the type of BH4 deficiency either due to defects in the genes encoding the enzymes involved in BH4 biosynthesis, GTPcyclohydrolase I (GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTPS), and sepiapterin reductase (SR); or defects in the genes encoding the enzymes involved in BH4 recycling, pterin-4a-carbinolamine dehydratase (PCD) and dihydropteridine reductase (DHPR)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Phenylalanine(Phe) Levels Measured at Specified Timepoints</measure>
    <time_frame>At Baseline, Week 4 through Extension Week 130</time_frame>
    <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The ideal range for blood Phe levels is approximately 120-360 µmol/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Blood Phenylalanine (Last Observation Carried Forward) &lt; 360 μmol/L</measure>
    <time_frame>At Baseline, Week 4 through Extension Week 130</time_frame>
    <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The objective of this outcome was to compare to Phe levels achieved using previous treatment regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Experiencing Adverse Events(AEs)</measure>
    <time_frame>Up to 35 Months</time_frame>
    <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.&#xD;
Mild = AE did not limit usual activities.&#xD;
Moderate = AE resulted in some limitation of usual activities.&#xD;
Severe = AE resulted in an inability to carry out usual activities.&#xD;
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration.&#xD;
Serious AE (SAE) resulted in death, was life-threatening, required in patient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect; or was an important medical event.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AEs Consistent With Signs and/or Symptoms of BH4 Deficiency</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>Attention was paid to AEs that may be consistent with signs and/or symptoms associated with primary BH4 deficiency to determine if such signs and symptoms arose or increased in severity or frequency during the study. These included prematurity and low birth weight, inability to control body temperature, low muscle tone, decreased spontaneous movements, poor sucking, movement disorders, difficulty swallowing, hypersalivation, seizures or convulsions, behavioral problems, developmental delay, and mental retardation.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Tetrahydrobiopterin Deficiencies</condition>
  <condition>Hyperphenylalaninemia, Non-Phenylketonuric</condition>
  <arm_group>
    <arm_group_label>Single Arm on Active Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels&#xD;
Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenoptin</intervention_name>
    <description>5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels</description>
    <arm_group_label>Single Arm on Active Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented history of blood Phe level &gt; 180 µmol/L on at least one occasion&#xD;
&#xD;
          -  Established diagnosis of hyperphenylalaninemia (HPA) due to primary BH4 deficiency&#xD;
             with a documented defect in biopterin metabolism with blood or urine tests&#xD;
&#xD;
          -  Willing and able to provide written informed consent or, in the case of subjects under&#xD;
             the age of 18 years, provide written assent (if required) and written informed consent&#xD;
             by a parent or legal guardian&#xD;
&#xD;
          -  Negative urine pregnancy test at screening for females of child-bearing potential&#xD;
&#xD;
          -  Male and female subjects of childbearing potential (if sexually active and&#xD;
             non-sterile) must be using acceptable birth control measures and be willing to&#xD;
             continue to use acceptable birth control measures, as determined by the Investigator,&#xD;
             and be willing to continue to use acceptable birth control measures while&#xD;
             participating in the study&#xD;
&#xD;
          -  Willing and able to comply with all study procedures&#xD;
&#xD;
          -  Able to take medication orally&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Perceived to be unreliable or unavailable for study participation or, if under the age&#xD;
             of 18 years, have parents or legal guardians who are perceived to be unreliable or&#xD;
             unavailable&#xD;
&#xD;
          -  Use of any investigational agent (other than BH4) within 30 days prior to screening,&#xD;
             or requirement for any investigational agent or vaccine prior to completion of all&#xD;
             scheduled study assessments&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (non-sterile females of child bearing&#xD;
             potential only), already known to be pregnant or breastfeeding or planning a pregnancy&#xD;
             in self or partner during the study&#xD;
&#xD;
          -  Female subjects of childbearing potential not using an effective method of birth&#xD;
             control, as determined by the PI, or unwilling to continue to use acceptable birth&#xD;
             control measures.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 2 times the upper limit of normal (i.e., Grade 1 or&#xD;
             higher based on World Health Organization Toxicity Criteria) at screening&#xD;
&#xD;
          -  Concurrent disease or condition that would interfere with study participation or&#xD;
             safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition&#xD;
             requiring oral or parenteral corticosteroid administration, insulin-dependent&#xD;
             diabetes, or organ transplantation)&#xD;
&#xD;
          -  Serious neuropsychiatric illness (e.g., major depression) not currently under medical&#xD;
             control&#xD;
&#xD;
          -  Requirement for concomitant treatment with any drug known to inhibit folate synthesis&#xD;
             (e.g., methotrexate)&#xD;
&#xD;
          -  Clinical diagnosis of phenylketonuria (PKU) due to phenylalanine hydroxylase&#xD;
             deficiency&#xD;
&#xD;
          -  Any condition that, in the view of the PI, renders the subject at high risk from&#xD;
             treatment compliance and/or completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biomarinpharm.com</url>
    <description>sponsor website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2006</study_first_posted>
  <results_first_submitted>September 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was a multicenter study, conducted at 8 sites in the United States of America and one site in Germany</recruitment_details>
      <pre_assignment_details>A sample size planned of 10 to 15 subjects considered adequate based on clinical considerations. Actual enrolled and treated are 12 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phenoptin</title>
          <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of Tetrahydrobiopterin (BH4) at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half of the dose was administered orally twice daily, to achieve a full dose per day.&#xD;
In Part 3 (concurrent with Extension), subjects had the option of receiving 10 mg/kg/day Phenoptin administered orally twice daily for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects that completed Part 2 were offered the option of participating in Part 3. Among 12 subjects, 2 participated in Part 3 that took place concurrent with the Extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3 (7 Weeks of Extension)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension (Variable Duration)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenoptin</title>
          <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, administered orally twice for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin.&#xD;
The mean Phenoptin dose received during the study was 9.1 mg/kg/day with a minimum of 1.9 mg/kg/day and a maximum of 21 mg/kg/day.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 are offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.5" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18 and &lt;65 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142.1" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Enzyme Defects</title>
          <description>Subjects were classified into 2 groups (synthesis and recycling groups) based on the response to a medical history query as to the type of enzymatic defect that caused primary BH4 deficiency in each subject. Nine (75.0%) subjects had defects in enzymes involved in BH4 biosynthesis and formed the synthesis group. Three subjects (25.0%) had defects in enzymes involved in recycling BH4 from an oxidized form back to an active reduced state.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Synthesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recycling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Phe at Screening Visit</title>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.5" spread="186.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Phenylalanine(Phe) Levels Measured at Specified Timepoints</title>
        <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The ideal range for blood Phe levels is approximately 120-360 µmol/L.</description>
        <time_frame>At Baseline, Week 4 through Extension Week 130</time_frame>
        <population>Efficacy analysis population are the subjects received at least 1 dose of Phenoptin and has at least 1 post-treatment measurement of blood Phe.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, half a dose administered orally twice daily for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 are offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
          </group>
          <group group_id="O2">
            <title>Subgroup: Subjects With Synthesis Enzymatic Defect</title>
            <description>Subjects primary BH4 deficiency due to defects in the genes encoding the enzymes involved in BH4 biosynthesis, guanosine triphosphate (GTP) cyclohydrolase I (GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTPS), and sepiapterin reductase (SR).</description>
          </group>
          <group group_id="O3">
            <title>Subgroup: Subjects With Recycling Enzyme Defect</title>
            <description>Subjects with BH4 deficiency due to defects in the genes encoding the enzymes involved in BH4 recycling, pterin-4a-carbinolamine dehydratase (PCD) and dihydropteridine reductase (DHPR).</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Phenylalanine(Phe) Levels Measured at Specified Timepoints</title>
          <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The ideal range for blood Phe levels is approximately 120-360 µmol/L.</description>
          <population>Efficacy analysis population are the subjects received at least 1 dose of Phenoptin and has at least 1 post-treatment measurement of blood Phe.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.9" spread="134.7"/>
                    <measurement group_id="O2" value="72.2" spread="13.4"/>
                    <measurement group_id="O3" value="315.0" spread="180.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="66.7"/>
                    <measurement group_id="O2" value="78.2" spread="28.4"/>
                    <measurement group_id="O3" value="181.7" spread="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.8" spread="119.0"/>
                    <measurement group_id="O2" value="70.2" spread="17.2"/>
                    <measurement group_id="O3" value="272.7" spread="175.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.3" spread="106.8"/>
                    <measurement group_id="O2" value="66.6" spread="13.6"/>
                    <measurement group_id="O3" value="249.3" spread="156.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.2" spread="147.3"/>
                    <measurement group_id="O2" value="75.0" spread="11.5"/>
                    <measurement group_id="O3" value="347.7" spread="187.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" spread="76.5"/>
                    <measurement group_id="O2" value="63.8" spread="8.5"/>
                    <measurement group_id="O3" value="185.7" spread="123.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.0" spread="95.3"/>
                    <measurement group_id="O2" value="71.9" spread="16.6"/>
                    <measurement group_id="O3" value="204.3" spread="170.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.8" spread="164.2"/>
                    <measurement group_id="O2" value="78.8" spread="20.4"/>
                    <measurement group_id="O3" value="343.0" spread="261.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.4" spread="173.1"/>
                    <measurement group_id="O2" value="72.4" spread="17.7"/>
                    <measurement group_id="O3" value="388.3" spread="226.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.7" spread="93.8"/>
                    <measurement group_id="O2" value="72.0" spread="12.6"/>
                    <measurement group_id="O3" value="210.7" spread="161.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.0" spread="223.2"/>
                    <measurement group_id="O2" value="61.3" spread="12.1"/>
                    <measurement group_id="O3" value="428.0" spread="349.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.2" spread="305.8"/>
                    <measurement group_id="O2" value="63.8" spread="10.6"/>
                    <measurement group_id="O3" value="553.3" spread="494.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.2" spread="159.8"/>
                    <measurement group_id="O2" value="69.8" spread="21.7"/>
                    <measurement group_id="O3" value="419.3" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension : Week 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="119.4"/>
                    <measurement group_id="O2" value="73.1" spread="22.8"/>
                    <measurement group_id="O3" value="277.7" spread="171.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.9" spread="118.2"/>
                    <measurement group_id="O2" value="74.6" spread="14.9"/>
                    <measurement group_id="O3" value="276.0" spread="173.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Blood Phenylalanine (Last Observation Carried Forward) &lt; 360 μmol/L</title>
        <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The objective of this outcome was to compare to Phe levels achieved using previous treatment regimens.</description>
        <time_frame>At Baseline, Week 4 through Extension Week 130</time_frame>
        <population>Efficacy analysis population are the subjects received at least 1 dose of Phenoptin and has at least 1 post-treatment measurement of blood Phe.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, administered orally twice for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin, either resumed with previously taken BH4 (tetrahydrobiopterin) formulations.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 are offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Blood Phenylalanine (Last Observation Carried Forward) &lt; 360 μmol/L</title>
          <description>Baseline blood phenylalanine(Phe) value is the latest measurement taken prior to initiation of Phenoptin treatment. The objective of this outcome was to compare to Phe levels achieved using previous treatment regimens.</description>
          <population>Efficacy analysis population are the subjects received at least 1 dose of Phenoptin and has at least 1 post-treatment measurement of blood Phe.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="73.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="73.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="42.8" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extension: Week 130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Experiencing Adverse Events(AEs)</title>
        <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.&#xD;
Mild = AE did not limit usual activities.&#xD;
Moderate = AE resulted in some limitation of usual activities.&#xD;
Severe = AE resulted in an inability to carry out usual activities.&#xD;
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration.&#xD;
Serious AE (SAE) resulted in death, was life-threatening, required in patient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect; or was an important medical event.</description>
        <time_frame>Up to 35 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenoptin</title>
            <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, administered orally twice for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 are offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Adverse Events(AEs)</title>
          <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.&#xD;
Mild = AE did not limit usual activities.&#xD;
Moderate = AE resulted in some limitation of usual activities.&#xD;
Severe = AE resulted in an inability to carry out usual activities.&#xD;
A treatment-emergent Adverse Events (TEAE) is any Adverse Events that newly appeared, increased in frequency or worsened in severity following initiation of study drug administration.&#xD;
Serious AE (SAE) resulted in death, was life-threatening, required in patient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect; or was an important medical event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Drug-Related Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal from study due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal from Study due to SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>AEs Consistent With Signs and/or Symptoms of BH4 Deficiency</title>
        <description>Attention was paid to AEs that may be consistent with signs and/or symptoms associated with primary BH4 deficiency to determine if such signs and symptoms arose or increased in severity or frequency during the study. These included prematurity and low birth weight, inability to control body temperature, low muscle tone, decreased spontaneous movements, poor sucking, movement disorders, difficulty swallowing, hypersalivation, seizures or convulsions, behavioral problems, developmental delay, and mental retardation.</description>
        <time_frame>Up to 35 months</time_frame>
        <population>AEs that are signs and symptoms of BH4 deficiency were reported for 3 subjects: One SAE of mild dyskinesia (required hospitalization) in one subject; events of severe dystonia and moderate Dyskinesia in one subject; and one event of mild vertigo in one subject. All events resolved and were considered unrelated to Phenoptin except mild vertigo.</population>
        <group_list>
          <group group_id="O1">
            <title>Phenoptin</title>
            <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, administered orally twice for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 were offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
          </group>
        </group_list>
        <measure>
          <title>AEs Consistent With Signs and/or Symptoms of BH4 Deficiency</title>
          <description>Attention was paid to AEs that may be consistent with signs and/or symptoms associated with primary BH4 deficiency to determine if such signs and symptoms arose or increased in severity or frequency during the study. These included prematurity and low birth weight, inability to control body temperature, low muscle tone, decreased spontaneous movements, poor sucking, movement disorders, difficulty swallowing, hypersalivation, seizures or convulsions, behavioral problems, developmental delay, and mental retardation.</description>
          <population>AEs that are signs and symptoms of BH4 deficiency were reported for 3 subjects: One SAE of mild dyskinesia (required hospitalization) in one subject; events of severe dystonia and moderate Dyskinesia in one subject; and one event of mild vertigo in one subject. All events resolved and were considered unrelated to Phenoptin except mild vertigo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with Any Signs and/or Symptoms of BH4 Def</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dystonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyskinesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertigo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 35 months (from enrollment to Study Completion.)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phenoptin</title>
          <description>In Part 1, subjects continued their usual treatment regimen.&#xD;
In Part 2, subjects on non-registered formulations of BH4 at enrollment began Phenoptin treatment at approximately the same daily dose; subjects not receiving BH4 at enrollment began treatment at 5mg/kg/day Phenoptin. Half a dose was administered orally twice daily, to achieve a full dose/day.&#xD;
In Part 3, subjects receives 10 mg/kg/day Phenoptin, administered orally twice for three weeks, followed by 20 mg/kg/day once daily for remaining 4 weeks.&#xD;
In extension phase, subjects were offered the option to continue treatment with Phenoptin, either resumed with previously taken BH4 (tetrahydrobiopterin) formulations.&#xD;
All 12 subjects participated in Part 1, Part 2 and Extension Phase. Subjects completed Part 2 are offered the option of participating in Part 3, Subjects who agreed to participate proceeded to Part 3. Among 12 subjects, 2 participated in Part 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical Device Change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Metabolic function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the small sample size in this study, a single patient AE exceeded the 5% maximum AE reporting threshold. Many of these manifestations are due to primary BH4 deficiency disease and the associated inadequate neurotransmitters.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joshua Lilienstein</name_or_title>
      <organization>BioMarin Pharmaceutical Inc.</organization>
      <phone>651-523-0310</phone>
      <email>MEDINFO@bmrn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

